Michael Ulz
Stock Analyst at Morgan Stanley
(4.72)
# 199
Out of 5,182 analysts
109
Total ratings
63.77%
Success rate
33.76%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $95 → $130 | $71.78 | +81.11% | 9 | Apr 21, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Upgrades: Overweight | $78 → $100 | $70.13 | +42.59% | 8 | Apr 21, 2026 | |
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $21 → $15 | $8.60 | +74.42% | 9 | Mar 25, 2026 | |
| CABA Cabaletta Bio | Maintains: Overweight | $14 → $13 | $2.86 | +354.55% | 7 | Mar 24, 2026 | |
| DYN Dyne Therapeutics | Maintains: Overweight | $50 → $47 | $18.16 | +158.81% | 4 | Mar 3, 2026 | |
| AARD Aardvark Therapeutics | Downgrades: Equal-Weight | $29 → $7 | $5.59 | +25.22% | 2 | Mar 2, 2026 | |
| GUTS Fractyl Health | Downgrades: Equal-Weight | $8 → $2 | $0.66 | +204.74% | 3 | Jan 30, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $95 → $123 | $94.06 | +30.77% | 6 | Jan 30, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $495 → $408 | $302.11 | +35.05% | 13 | Jan 30, 2026 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $20 → $25 | $8.70 | +187.36% | 3 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $98 → $102 | $32.39 | +214.91% | 4 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $25 | $7.70 | +224.68% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $3.38 | +491.72% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $1.30 | +438.46% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $9.65 | +179.79% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $0.96 | +1,993.58% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $3.43 | +1,211.95% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $140 | $7.88 | +1,676.65% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $6.30 | -52.38% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $10.28 | +191.83% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $24.53 | +226.13% | 3 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $14.49 | +3.52% | 3 | Jul 12, 2017 |
Ionis Pharmaceuticals
Apr 21, 2026
Maintains: Overweight
Price Target: $95 → $130
Current: $71.78
Upside: +81.11%
Arrowhead Pharmaceuticals
Apr 21, 2026
Upgrades: Overweight
Price Target: $78 → $100
Current: $70.13
Upside: +42.59%
Karyopharm Therapeutics
Mar 25, 2026
Maintains: Outperform
Price Target: $21 → $15
Current: $8.60
Upside: +74.42%
Cabaletta Bio
Mar 24, 2026
Maintains: Overweight
Price Target: $14 → $13
Current: $2.86
Upside: +354.55%
Dyne Therapeutics
Mar 3, 2026
Maintains: Overweight
Price Target: $50 → $47
Current: $18.16
Upside: +158.81%
Aardvark Therapeutics
Mar 2, 2026
Downgrades: Equal-Weight
Price Target: $29 → $7
Current: $5.59
Upside: +25.22%
Fractyl Health
Jan 30, 2026
Downgrades: Equal-Weight
Price Target: $8 → $2
Current: $0.66
Upside: +204.74%
Mirum Pharmaceuticals
Jan 30, 2026
Maintains: Overweight
Price Target: $95 → $123
Current: $94.06
Upside: +30.77%
Alnylam Pharmaceuticals
Jan 30, 2026
Maintains: Equal-Weight
Price Target: $495 → $408
Current: $302.11
Upside: +35.05%
Kyverna Therapeutics
Dec 4, 2025
Maintains: Overweight
Price Target: $20 → $25
Current: $8.70
Upside: +187.36%
Oct 23, 2025
Maintains: Overweight
Price Target: $98 → $102
Current: $32.39
Upside: +214.91%
May 9, 2025
Maintains: Overweight
Price Target: $45 → $25
Current: $7.70
Upside: +224.68%
Feb 28, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $3.38
Upside: +491.72%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $1.30
Upside: +438.46%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $9.65
Upside: +179.79%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $0.96
Upside: +1,993.58%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $3.43
Upside: +1,211.95%
Jan 27, 2023
Maintains: Overweight
Price Target: $280 → $140
Current: $7.88
Upside: +1,676.65%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $6.30
Upside: -52.38%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $10.28
Upside: +191.83%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $24.53
Upside: +226.13%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $14.49
Upside: +3.52%